No benefit of treatment with cyclophosphamide and autologous blood stem cell transplantation in multifocal motor neuropathy

Acta Neurol Scand. 2008 Jun;117(6):432-4. doi: 10.1111/j.1600-0404.2007.00970.x. Epub 2007 Dec 12.

Abstract

Introduction: Patients with multifocal motor neuropathy (MMN) usually respond to intravenous immunoglobulin (IVIG), but because of the short-lasting effect the treatment must be given repeatedly. Remission after treatment with high-dose cyclophosphamide has recently been reported in one patient refractory to IVIG.

Case report: Here we report on a patient who responded to IVIG, but temporarily deteriorated dramatically after treatment with high-dose cyclophosphamide and autologous blood stem cell transplantation. Today the situation is the same as before the treatment with cyclophosphamide and blood stem cell transplantation, i.e. IVIG is given every 4 weeks.

Conclusion: Our patient did not benefit from the treatment with high-dose cyclophosphamide and autologous blood stem cell transplantation. The effect of treatment with high-dose cyclophosphamide in MMN seems to be difficult to predict and that should be paid attention to if this type of treatment is considered.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Combined Modality Therapy
  • Cyclophosphamide / therapeutic use*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Motor Neuron Disease / drug therapy
  • Motor Neuron Disease / therapy*
  • Transplantation, Autologous
  • Treatment Failure

Substances

  • Immunoglobulins, Intravenous
  • Immunosuppressive Agents
  • Cyclophosphamide